1. Percent change in apparent diffusion coefficient and plasma EBV DNA after induction chemotherapy identifies distinct prognostic response phenotypes in advanced nasopharyngeal carcinoma
- Author
-
Li-Ting Liu, Shan-Shan Guo, Hui Li, Chao Lin, Rui Sun, Qiu-Yan Chen, Yu-Jing Liang, Qing-Nan Tang, Xue-Song Sun, Lin-Quan Tang, Chuan-Miao Xie, and Hai-Qiang Mai
- Subjects
Adult ,Male ,Herpesvirus 4, Human ,Cancer Research ,Nasopharyngeal Carcinoma ,Adolescent ,Research ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Induction Chemotherapy ,Middle Aged ,Prognosis ,EBV DNA ,Response phenotypes ,Young Adult ,Diffusion Magnetic Resonance Imaging ,Apparent diffusion coefficient ,Oncology ,DNA, Viral ,Disease Progression ,Genetics ,Humans ,Female ,RC254-282 ,Aged - Abstract
Background To evaluate the prognostic value of the apparent diffusion coefficient (ADC) derived from diffusion-weighted magnetic resonance imaging (MRI) and monitor the early treatment response to induction chemotherapy (IC) with plasma EBV DNA in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Results A total of 307 stage III-IVb NPC patients were prospectively enrolled. All patients underwent MRI examinations to calculate ADC and plasma EBV DNA measurements pretreatment and post-IC. The participants’ ADC value of 92.5% (284/307) increased post-IC. A higher percent change in ADC value (ΔADC%high group) post-IC was associated with a higher 5-year OS rate (90.7% vs 74.9%, p low group. Interestingly, ΔADC% was closely related to the response measured by RECIST 1.1 (p p = 0.037). The AUC significantly increased when post-IC plasma EBV DNA was added to ΔADC% to predict treatment failure. Thus, based on ΔADC% and plasma EBV DNA, we further divided the participants into three new prognostic response phenotypes (early response, intermediate response, and no response) that correlated with disparate risks of death (p = 0.001), disease progression (p p p Conclusion The percentage change in ADC post-IC is indicative of treatment response and clinical outcome. ΔADC% and plasma EBV DNA-based response phenotypes may provide potential utility for early termination of treatment and allow guiding risk-adapted therapeutic strategies for LA-NPC.
- Published
- 2021